Exploring the addition of for example biotinylated Spycatcher‐recombinant VAR2CSA malaria protein [27, 28] to biotinylated EpCAM blood samples of cancer patients in which a relatively low number of CTC are detected targeting EpCAM such as nonsmall cell lung cancer, ovarium, pancreas, and colorectal cancer [29, 30] will show whether or not broadening of the target antigens and improving the capture efficiency of low target antigens will improve the enrichment of tumor cells in the blood. This evidence concerns the gene EPCAM and cancer.